Pages that link to "Q28262538"
Jump to navigation
Jump to search
The following pages link to Antibody therapy of cancer (Q28262538):
Displaying 50 items.
- Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies (Q21131216) (← links)
- Antibody therapies for lymphoma in children (Q24186437) (← links)
- Antibody therapies for lymphoma in children (Q24195106) (← links)
- Immunoregulatory functions of immune complexes in vaccine and therapy (Q26738396) (← links)
- Aptamers: A Feasible Technology in Cancer Immunotherapy (Q26740303) (← links)
- Augmenting the Efficacy of Immunotoxins and Other Targeted Protein Toxins by Endosomal Escape Enhancers (Q26744722) (← links)
- Immune Cells in Cancer Therapy and Drug Delivery (Q26747061) (← links)
- The Molecular Architecture of Cell Adhesion: Dynamic Remodeling Revealed by Videonanoscopy (Q26747246) (← links)
- CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas (Q26749139) (← links)
- Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction (Q26749333) (← links)
- Recent developments in receptor tyrosine kinases targeted anticancer therapy (Q26751331) (← links)
- Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers (Q26751473) (← links)
- T cell receptor mimic antibodies for cancer therapy (Q26768271) (← links)
- Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer (Q26769958) (← links)
- Targeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer Treatment (Q26769963) (← links)
- Targeted Radionuclide Therapy of Human Tumors (Q26771267) (← links)
- Recent advances in the field of anti-cancer immunotherapy (Q26775602) (← links)
- Production of monoclonal antibodies in plants for cancer immunotherapy (Q26778423) (← links)
- Immune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer Therapeutics (Q26784480) (← links)
- Perspectives in the treatment of pancreatic adenocarcinoma (Q26797248) (← links)
- Recapitulating the Tumor Ecosystem Along the Metastatic Cascade Using 3D Culture Models (Q26797285) (← links)
- NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy (Q26797345) (← links)
- Challenges in Antibody Development against Tn and Sialyl-Tn Antigens (Q26798183) (← links)
- Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy (Q26798404) (← links)
- Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives (Q26799104) (← links)
- Exosomic microRNAs in the Tumor Microenvironment (Q26799945) (← links)
- Antibody-drug conjugates as novel anti-cancer chemotherapeutics (Q26800175) (← links)
- A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy (Q26824462) (← links)
- Photodynamic nanomedicine in the treatment of solid tumors: perspectives and challenges (Q26827820) (← links)
- Cancer wars: natural products strike back (Q26850074) (← links)
- Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses (Q26851802) (← links)
- Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells (Q26852287) (← links)
- Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity (Q26862220) (← links)
- Blocking monoclonal antibodies of TIM proteins as orchestrators of anti-tumor immune response (Q26863081) (← links)
- Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges (Q26866236) (← links)
- Tetraspanins as therapeutic targets in hematological malignancy: a concise review (Q27002353) (← links)
- Active and passive immunization for cancer (Q27015783) (← links)
- Can nanomedicines kill cancer stem cells? (Q27022017) (← links)
- Nanotechnology in cancer therapy (Q27023013) (← links)
- Quantitative in vivo cell-surface receptor imaging in oncology: kinetic modeling and paired-agent principles from nuclear medicine and optical imaging (Q27023605) (← links)
- Multi-stimuli responsive Cu2S nanocrystals as trimodal imaging and synergistic chemo-photothermal therapy agents (Q27335134) (← links)
- CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes (Q27341786) (← links)
- Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies (Q27680195) (← links)
- Theranostic applications of antibodies in oncology. (Q27693293) (← links)
- Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies (Q27694769) (← links)
- Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motion (Q28066285) (← links)
- The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs (Q28066801) (← links)
- Development of Novel Immunotherapies for Multiple Myeloma (Q28066890) (← links)
- Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma (Q28072320) (← links)
- A current perspective on applications of macrocyclic-peptide-based high-affinity ligands (Q28072407) (← links)